肌少症操作模型的批判性评估:肌肉衰竭该测量什么
本文指出,肌少症目前基于专家意见的定义导致患病率报告差异大、对不良结局预测不一致,并阻碍有效非药物和药物疗法及生物标志物研发。作者呼吁整合生理表面效度与临床适用性,重新审视肌少症的操作模型。
要点
- 现行肌少症定义主要基于专家意见,缺乏明确方法学依据。
- 定义模糊导致患病率报告差异大,对不良结局预测不一致。
- 需整合生理表面效度与临床适用性,修订肌少症操作模型。
核心结论
- 现行肌少症操作模型主要基于专家意见,未整合分层证据与先进统计方法,其临床准确性存疑。
- 定义模糊导致患病率差异大、结局预测不一致,并阻碍疗法与生物标志物研发。
研究设计与样本
- 本文为个人观点(Personal View)文章,批判性审视当前肌少症研究现状。
主要发现
- 肌少症最初概念为描述 unsuccessful ageing 对60岁及以上老年人维持独立移动能力影响的神经肌肉状况。
- 现行定义主要基于专家意见,未清晰说明诊断标准的优先排序方法。
- 定义模糊导致患病率报告差异大、对不良结局预测不一致,并给非药物和药物疗法及可靠生物标志物开发带来重大挑战。
临床怎么用
- 临床应认识到现行肌少症诊断标准基于专家意见,存在不确定性。
- 在评估肌肉衰竭时需关注生理表面效度与临床适用性的整合。
局限性
- 本文为个人观点文章,未提供原始研究数据或系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcopenia was originally conceptualised to describe a neuromuscular condition that could help to explain, at least partly, the effect of unsuccessful ageing on the ability of older adults (ie, those aged 60 years and older) to maintain independent mobility. Over time, international committees have standardised the definition and operationalisation of sarcopenia. However, a key issue in diagnosing sarcopenia remains as the current definitions are primarily based on expert opinion, with no clear explanation or description of the method used to prioritise the diagnostic criteria for sarcopenia, rather than on the integration of subjective methods (eg, expert opinion) with hierarchical evidence and advanced statistical methodologies. This issue has led to considerable variability in the reported prevalence rates of sarcopenia, inconsistent findings regarding sarcopenia as a predictor of adverse outcomes, and major challenges in the development of effective non-pharmacological (eg, physical exercise, nutrition), pharmacological therapies, or reliable biomarkers of disease status. The ambiguity on what is being measured under the present definitions of sarcopenia raises the fundamental question of whether these models truly represent the most accurate and clinically useful constructs of age-related muscle failure. In this Personal View, we critically examine the current state of sarcopenia research and highlight the need for a revised approach that integrates physiological face validity and clinical applicability.
引用
- Coelho-Júnior HJ, Marzetti E. Capturing what counts in muscle failure: a critical appraisal of the current operational models of sarcopenia. Lancet Healthy Longev. 2025. PMID: 40885204. doi:10.1016/j.lanhl.2025.100756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。